Clinical utility of laboratory tests used to identify antiphospholipid antibodies and to diagnose the antiphospholipid syndrome

Seminars in Thrombosis and Hemostasis

Volumn 34, Issue 4, 2008, Pages 329-334

  Galli, Monica ^a,b  

^a OSPEDALI RIUNITI   (Italy)

^b Department of Hematology ^*  (Italy)

Author keywords

Anti 2 glycoprotein i antibodies; Antiphospholipid antibodies; Antiphospholipid syndrome; Lupus anticoagulants; Thrombosis

Indexed keywords

BETA2 GLYCOPROTEIN 1 ANTIBODY; CARDIOLIPIN ANTIBODY; LUPUS ANTICOAGULANT; PHOSPHOLIPID ANTIBODY;

ANTIBODY DETECTION; ANTIPHOSPHOLIPID SYNDROME; BLOOD CLOTTING TEST; ENZYME LINKED IMMUNOSORBENT ASSAY; HUMAN; IMMUNOASSAY; LABORATORY TEST; PRACTICE GUIDELINE; PRIORITY JOURNAL; REVIEW; THROMBOSIS;

ANTIBODIES, ANTICARDIOLIPIN; ANTIPHOSPHOLIPID SYNDROME; BETA 2-GLYCOPROTEIN I; FEMALE; HEMATOLOGIC TESTS; HUMANS; IMMUNOGLOBULIN G; IMMUNOGLOBULIN M; LUPUS COAGULATION INHIBITOR; MALE; PREGNANCY; PREGNANCY COMPLICATIONS, HEMATOLOGIC; THROMBOSIS; TIME FACTORS;

EID: 50249117873     PISSN: 00946176     EISSN: 10989064     Source Type: Journal    
DOI: 10.1055/s-0028-1085474     Document Type: Review

References (50)

1. Wilson WA, Gharavi AE, Koike T, et al. International consensus statement on preliminary classification criteria for definite antiphospholipid syndrome. Arthritis Rheum 1999;42:1309-1311
2. Miyakis S, Lockshin MD, Atsumi T, et al. International consensus statement on an update of the classification criteria for definite antiphospholipid syndrome (APS). J Thromb Haemost 2006;4:295-306
3. Brandt JT, Triplett DA, Alving B, Scharrer I. Criteria for the diagnosis of lupus anticoagulants: an update. Thromb Haemost 1995;74:1185-1190
4. Galli M, Luciani D, Bertolini G, Barbui T. Antiβ2-glycoprotein I, antiprothrombin antibodies and the risk of thrombosis in the antiphospholipid syndrome. Blood 2003;102:2717-2723
5. Reber G, Arvieux J, Comby E, et al. Multicenter evaluation of nine commercial kits for the quantitation of anticardiolipin antibodies. The Working Group on Methodologies in Haemostasis from the GEHT (Groupe d'Etudes sur l'Hemostase et la Thrombose). Thromb Haemost 1995;73:444-452
6. Tincani A, Allegri F, Sanmarco M, et al. Anticardiolipin antibody assay: a methodological analysis for a better consensus in routine determinations - a cooperative project of the European Antiphospholipid Forum. Thromb Haemost 2001;86:575-583
7. Favaloro EJ, Silvestrini R. Assessing the usefulness of anticardiolipin antibody assays: a cautious approach is suggested by high variation and limited consensus in multilaboratory testing. Am J Clin Pathol 2002;118:548-557
8. Tincani A, Allegri F, Balestrieri G, et al. Minimal requirements for antiphospholipid antibodies ELISAs proposed by the European Forum on antiphospholipid antibodies. Thromb Res 2004;114:553-558
9. Reber G, Shousboe I, Tincani A, et al. Inter-laboratory variability of anti-beta2-glycoprotein I measurement. A collaborative study in the frame of the European Forum on Antiphospholipid Antibodies Standardization Group. Thromb Haemost 2002;88:66-73
10. Reber G, Tincani A, Sanmarco M, de Moerloose P, Boffa MC, for the European Forum on Antiphospholipid Antibodies Standardization Group. Variability of anti-beta2-glycoprotein I measurement by commercial assays. Thromb Haemost 2005;94:665-672
11. Favaloro EJ, Wong RC, Jovanovich S, Roberts-Thomson P. A review of beta2-glycoprotein I antibody testing results from a peer-driven multilaboratory quality assurance program. Am J Clin Pathol 2007;127:441-448
12. Pierangeli SS, Goldsmith GH, Krnic S, Harris EN. Difference in functional activity of anticardiolipin antibodies from patients with syphilis and those with the antiphospholipid syndrome. Infect Immun 1994;62:4081-4084
13. Hunt JE, McNeil HP, Morgan GJ, Crameri RM, Krilis SA. A phospholipid-beta 2-glycoprotein I complex is an antigen for anticardiolipin antibodies occurring in autoimmune disease but not with infection. Lupus 1992;1:75-81
14. Greaves M, Cohen H, Machin SI, Mackie I. Guidelines on the investigation and management of the antiphospholipid syndrome. Br J Haematol 2000;109:704-715
15. Bevers EM, Galli M, Barbui T, Comfurius P, Zwaal RFA. Lupus anticoagulant IgG's (LA) are not directed to phospholipids only, but to a complex of lipid-bound human prothrombin. Thromb Haemost 1991;66:629-632
16. Galli M, Comfurius P, Barbui T, Zwaal RFA, Bevers EM. Anticoagulant activity of β2-glycoprotein I is potentiated by a distinct subgroup of anticardiolipin antibodies. Thromb Haemost 1992;68:297-300
17. Horbach DA, van Oort E, Derksen RHWM, de Groot PG. The contribution of anti-prothrombin antibodies to the lupus anticoagulant activity - Discrimination between functional and non-function anti-prothrombin antibodies. Thromb Haemost 1998;79:790-795
18. Pengo V, Biasiolo A, Pegoraro C, Iliceto S. A two-step coagulation test to identify aβ2-glycoprotein I lupus antcoagulants. J Thromb Haemost 2004;2:702-727
19. Simmelink MJ, Derksen RHWM, Arnout J, de Groot PG. A simple method to discriminate between β2-glycoprotein I and prothrombin-dependent lupus anticoagulants. J Thromb Haemost 2003;1:740-747
20. De Laat HB, Derksen RHWM, Urbanus RT, Roest M, de Groot PG. β2-glycoprotein I-dependent lupus anticoagulant highly correlates with thrombosis in the antiphospholipid syndrome. Blood 2004;104:3598-3602
21. De Laat B, Derksen RHWM, Urbanus RT, de Groot PG. IgG antibodies that recognize epitope Gly40-Arg43 in domain I of β2-glycoprotein I cause LAC, and their presence correlates strongly with thrombosis. Blood 2005;105:1540-1545
22. Galli M, Luciani D, Bertolini G, Barbui T. Lupus anticoagulants are stronger risk factors of thrombosis than anticardiolipin antibodies in the antiphospholipid syndrome: a systematic review of the literature. Blood 2003;101:1827-1832
23. Opatrny L, David M, Kahn SR, Shrier I, Rey E. Association between antiphospholipid antibodies and recurrent fetal loss in women without autoimmune disease: a meta-analysis. J Rheumatol 2006;33:2214-2221
24. Male C, Foulon D, Hoogendoom H, et al. Predictive value of persistent versus transient antiphospholipid antibody subtypes for the risk of thrombotic events in pediatric patients with systemic lupus erythematosus. Blood 2005;106:4152-4158
25. Galli M, Borrelli G, Jacobsen EM, et al. Clinical significance of different antiphospholipid antibodies in the WAPS (warfarin in the antiphospholipid syndrome) study. Blood 2007;110:1178-1183
26. Naess IA, Christiansen SC, Cannegieter SC, Rosendaal FR, Hammerstroem J. A prospective study of anticardiolipin antibodies as a risk factor for venous thrombosis in a general population (the HUNT study). J Thromb Haemost 2006;4:44-49
27. Runchey SS, Folsom AR, Tsai MY, Cushman M, McGovern PD. Anticardiolipin antibodies as a risk factor for venous thromboembolism in a population-based prospective study. Br J Haematol 2002;119:1005-1010
28. Iverson GM, Victoria EJ, Marquis DM. Anti-beta2 glycoprotein I (beta2GPI) autoantibodies recognize an epitope on the first domain of beta2GPI. Proc Natl Acad Sci U S A 1998;95:15542-15546
29. McNeeley PA, Dlott JS, Furie RA, et al. β2-glycoprotein I-dependent anticardiolipin antibodies preferentially bind the amino terminal domain of β2-glycoprotein I. Thromb Haemost 2001;86:590-595
30. Koike T, Ichikawa K, Kasahara H, Atsumi T, Tsutsumi A, Matsuura E. Epitopes on β2-GPI recognized by anticardiolipin antibodies. Lupus 1998;7(Suppl 2):S14-S17
31. Hunt J, Krilis SA. The fifth domain of β2-glycoprotein I contains a phospholipids binding site (Cys281-Cys288) and a region recognized by anticardiolipin antibodies. J Immunol 1994;152:653-659
32. Pengo V, Biasiolo A, Pegoraro C, Cucchini U, Noventa F. Antibody profiles for the diagnosis of antiphospholipid syndrome. Thromb Haemost 2005;93:1147-1152
33. Forastiero R, Martinuzzo M, Pombo G, et al. A prospective study of antibodies to β2-GPI and prothrombin and risk of thrombosis. J Thromb Haemost 2005;3:1231-1238
34. Bizzaro N, Ghirardello A, Zampieri S, et al. Anti-prothrombin antibodies predict thrombosis in patients with systemic lupus erythematosus: a 15-year longitudinal study. J Thromb Haemost 2007;5:1158-1164
35. Loeliger A. Prothrombin as co-factor for the circulating anticoagulant in systemic lupus erythematosus? Thromb Diath Haemorrh 1959;3:327-356
36. Galli M, Barbui T. Antiprothrombin antibodies: detection and clinical significance in the antiphospholipid syndrome. Blood 1999;93:2149-2157
37. Arvieux J, Darnige L, Reber G, Bensa JC, Colomb MG. Development of an ELISA for autoantibodies to prothrombin showing their prevalence in patients with lupus anticoagulants. Thromb Haemost 1995;74:1120-1125
38. Galli M, Beretta G, Daldossi M, Bevers EM, Barbui T. Different anticoagulant and immunological properties of anti-prothrombin antibodies in patients with antiphospholipid antibodies. Thromb Haemost 1997;77:486-491
39. Atsumi T, Ieko M, Bertolaccini ML, et al. Association of autoantibodies against the phosphatidylserine-prothrombin complex with manifestations of the antiphospholipid syndrome and the presence of lupus anticoagulant. Arthritis Rheum 2000;43:1982-1993
40. Donohoe S, Mackie IJ, Isenberg D, Machin SI. Anti-prothrombin antibodies: assay conditions and clinical associations in the anti-phospholipid syndrome. Br J Haematol 2001;113:544-549
41. Galli M, Willems GM, Rosing J, et al. Anti-prothrombin IgG from patients with anti-phospholipid antibodies inhibits the inactivation of factor Va by activated protein C. Br J Haematol 2005;129:240-247
42. Field SL, Hogg PJ, Daly EB, et al. Lupus anticoagulants form immune complexes with prothrombin and phospholipid that can augment thrombin production in flow. Blood 1999;94:3421-3431
43. Lanir N, Aharon A, Brenner B. Procoagulant and anticoagulant mechanisms in human placenta. Semin Thromb Hemost 2003;29:175-184
44. van Ommen CH, van Wijnen M, de Groot PG, van der Horst CM, Peters J. Postvaricella purpura fulminans caused by acquired protein S deficiency resulting from antiprotein S antibodies: search for the epitopes. J Pediatr Hematol Oncol 2002;24:413-416
45. Kurugol Z, Vardar F, Ozkinay F, Kavakli K, Ozkinay C. Lupus anticoagulant and protein S deficiency in otherwise healthy children with acute varicella infection. Acta Paediatr 2000;89:1186-1189
46. Büller HR, Agnelli G, Hull RD, Hyers TM, Prins MH, Raskob GE. Antithrombotic therapy for venous thromboembolic disease. The seventh ACCP Conference on antithrombotic and thrombolytic therapy. Chest 2004;126:S401-S28
47. Crowther MA, Ginsberg JS, Julian J, et al. A comparison of two intensities of warfarin for the prevention of recurrent thrombosis in patients with the antiphospholipid antibody syndrome. N Engl J Med 2003;349:1133-1138
48. Finazzi G, Marchioli R, Brancaccio V, et al. A randomized clinical trial of high-intensity warfarin vs. conventional antithrombotic therapy for the prevention of recurrent thrombosis in patients with antiphospholipid syndrome (WAPS). J Thromb Haemost 2005;3:848-853
49. Khamashta MA, Hunt BJ. Moderate dose oral anticoagulant therapy in patients with the antiphospholipid syndrome? No. J Thromb Haemost 2005;3:844-845
50. Galli M, Reber G, De Moerloose P, deGroot PG. Invitation to a debate on the serological criteria that define the antiphospholipid syndrome. J Thromb Haemost 2008;6:399-401